Cancer therapy toxicity

Submission status
Submission deadline

Advances in cancer therapies including immunotherapy, chemotherapy, targeted agents, hormonal therapy, surgery, and radiation therapy have significantly improved cancer treatment and patient outcomes. However, these treatments can lead to a range of toxicities, which can significantly impact patients’ quality of life and long-term health. Understanding which patients are affected by treatment toxicity, and the reasons why, can help to inform strategies to manage adverse effects and develop novel therapies with reduced toxicities.

We invite submissions of primary research with a focus on minimizing and mitigating cancer therapy-related toxicity, and/or identifying new insights into the epidemiology and pathophysiology of both acute and late toxicities. We encourage submission of manuscripts describing the early detection, prediction, prevention, and patient-centered monitoring and management of cancer therapy-related toxicity. This includes studies evaluating the efficacy and safety of various interventions, such as supportive care measures, drug therapies, and lifestyle modifications, aimed at reducing toxicity and improving patient outcomes. We also welcome preclinical work that examines the mechanistic basis of cancer therapy-related toxicity, which may inform future mitigation approaches, or articles exploring the use of digital tools to minimize toxicity and improve management. Additionally, we are particularly eager to receive studies evaluating toxicities related to newer cancer therapeutic classes, such as cellular therapies. In addition to primary research, we welcome submissions of other article types, such as Reviews, Perspectives, and Comments that provide significant insights into the topic. All submissions will be subject to the same review process and editorial standards as regular Communications Medicine Articles.

Submit manuscript
Submission guidelines
Manuscript editing services
cancer pills


Dr. Raymond Mak is an Associate Professor of Radiation Oncology at Harvard Medical School and Brigham and Women’s Hospital/Dana-Farber Cancer Institute, USA. His research interests focus on developing imaging biomarkers to predict radiation therapy response in lung cancer patients and applying artificial intelligence techniques to automate radiation therapy planning. He has led crowd innovation and clinical trials to develop novel, clinically-relevant artificial intelligence techniques. Dr. Mak’s clinical focus includes treatment of thoracic malignancies and novel image-guided radiation therapy techniques.


Dr. Miranda Fidler-Benaoudia is a Cancer Epidemiologist/Research Scientist in the Department of Cancer Epidemiology and Prevention Research at Alberta Health Services, and an Adjunct Assistant Professor in the Departments of Oncology and Community Health Sciences at the University of Calgary, Canada. Her research focuses primarily on describing the burden of childhood, adolescent and young adult cancers and evaluating their related late-effects. She is additionally interested in sub-populations, such as indigenous peoples, and continues to undertake research comprehensively describing cancer indicators nationally, regionally and at global levels.


Dr. Lova Sun is an Assistant Professor in the Division of Hematology Oncology at the Perelman School of Medicine at the University of Pennsylvania, USA. She is a thoracic and head and neck medical oncologist and clinician investigator. Her research involves observational database studies as well as prospective clinical trials to improve treatment strategies and patient outcomes.